Penelope Brock

Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Bert C. Del Villano, Seamus P. Brennan, Penelope Brock et al. · Clinical Chemistry · 1983 · 506 citations

Life Sciences, Immunology, Oncology +15

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

Johan Maertens, Jan Verhaegen, Hilde Demuynck et al. · Journal of Clinical Microbiology · 1999 · 376 citations · Full text

Life Sciences, Hematology, Microbiology +14

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

Penelope Brock, Rudolf Maibach, Margaret Childs et al. · New England Journal of Medicine · 2018 · 369 citations · Full text

Medicine, Oncology, Otolaryngology +17

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8